Evidence map›Paper›PMID 41055954›Full record

ArticleJCI insight2025

Rheumatoid arthritis synovial fibroblasts modulate T cell activation.

Melissa R Romoff, Preethi K Periyakoil, Edward F DiCarlo, Daniel Ramirez, Susan M Goodman, Christina S Leslie, Alexander Y Rudensky, Laura T Donlin, Melanie H Smith

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Fibroblast heterogeneity in 2025.Nature reviews. Rheumatology · 2026
    Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Melissa R RomoffResearch Institute, Hospital for Special Surgery, New York, New York, USA.
Preethi K PeriyakoilComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Edward F DiCarloDepartment of Pathology and Laboratory Medicine, and.
Daniel RamirezDepartment of Pathology and Laboratory Medicine, and.
Susan M GoodmanDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, New York, USA.
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alexander Y RudenskyHoward Hughes Medical Institute and Immunology Program at Sloan Kettering Institute, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Laura T DonlinResearch Institute, Hospital for Special Surgery, New York, New York, USA.
Melanie H SmithResearch Institute, Hospital for Special Surgery, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune InflammationU01HG012103 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI Christina S Leslie, Alexander Y Rudensky · 2021 to 2026
$7.5M
Weill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6M
SELF PEPTIDES BOUND TO MHC CLASS II IN T CELL SELECTIONR01AI034206 · NIAID · UNIVERSITY OF WASHINGTON · PI Alexander Y Rudensky · 1998 to 2026
$6.4M
Self Peptides Bound to MHC Class II In T Cell SelectionR37AI034206 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI RUDENSKY, ALEXANDER Y · 2009 to 2018
$4.8M
Macrophages in human autoimmune tissue pathologyR01AI148435 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI Laura T. Donlin · 2020 to 2026
$2.8M
HSS Research Institute Rheumatology TrainingT32AR071302 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI ALESSANDRA B PERNIS, Jane E Salmon · 2017 to 2026
$2.3M
Activation of Synovial Lining Fibroblasts in Rheumatoid ArthritisK08AR082929 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Melanie Hennebry Smith · 2024 to 2026
$528k
NCI NIH HHS P30 CA008748NHGRI NIH HHS U01 HG012103NIAID NIH HHS R01 AI034206NIAID NIH HHS R01 AI148435NIAID NIH HHS R37 AI034206NIAMS NIH HHS K08 AR082929NIAMS NIH HHS T32 AR071302NIGMS NIH HHS T32 GM152349
6 · The paper itself

Abstract

In the rheumatoid arthritis (RA) synovium, resident fibroblast-like synoviocytes (FLS) express MHC class II molecules (HLA-D) but lack the costimulatory signals typically required for T cell activation. Here, we demonstrate that antigen presentation by FLS induces a distinct T cell activation state characterized by high CD69 yet reduced CD25 and HLA-DR expression, suppressed proliferation, and decreased effector cytokine production compared with professional antigen-presenting cells (APCs), such as macrophages. FLS were also capable of suppressing macrophage-induced T cell activation, underscoring their dominant immunomodulatory role in the synovial microenvironment. Mechanistically, we identify indoleamine 2,3-dioxygenase-mediated (IDO1-mediated) tryptophan depletion as the primary driver of FLS-induced T cell hyporesponsiveness. Spatial transcriptomics revealed colocalization of IDO1 and CD69 within ectopic lymphoid structures in RA synovium, further supporting the in vivo relevance of this pathway. These findings provide the groundwork for positioning FLS as critical T cell regulators in RA and highlight the importance of preserving their immunosuppressive properties when therapeutically targeting pathogenic FLS functions.

Indexed as

Arthritis, RheumatoidFibroblastsLymphocyte ActivationSynovial MembraneSynoviocytesT-LymphocytesAntigen PresentationAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensFemaleHumansIndoleamine-Pyrrole 2,3,-DioxygenaseLectins, C-TypeMacrophagesMaleAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseLectins, C-TypeAutoimmunityImmunologyRheumatology

Identifiers

PMID41055954
PMCPMC12643496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.